InBody : Report on Business Performance according to Consolidated Financial Statements (Fair Disclosure)
February 25, 2022 at 12:22 pm IST
Share
Report on Business Performance according to Consolidated Financial Statements (Fair Disclosure)
※ The information contained in this report is estimated, it is subject to change according to actual settlement.
1. Details of Business Performance
Classification(unit : Mil.KRW, %)
Current Term
Previous Term
Amount Increased/Decreased Compared to the Preceding Period(Increase/Decrease Rate)
Corresponding Period of The Previous Year
Amount Increased/Decreased Compared to the Corresponding Period of The Previous Year (Increase/Decrease Rate)
(2021 4Q)
(2021 3Q)
(2020 4Q)
Sales
Amount
38,005
33,042
4,963(15.0%)
28,930
9,075(31.4%)
Accumulated Amount
137,837
-
-
107,122
30,715(28.7%)
Operating Income
Amount
9,375
7,915
1,460(18.4%)
6,266
3,109(49.6%)
Accumulated Amount
36,299
-
-
19,097
17,202(90.1%)
Profit from continuing operation before corporate income tax
Amount
8,743
8,905
-162(-1.8%)
6,882
1,861(27.0%)
Accumulated Amount
39,330
-
-
20,668
18,662(90.3%)
Net Income
Amount
8,737
7,074
1,663(23.5%)
6,288
2,449(38.9%)
Accumulated Amount
34,142
-
-
17,555
16,587(94.5%)
Net Income Attributable to the Shareholders of the Parent Company
Amount
8,739
7,069
1,670(23.6%)
6,275
2,464(39.3%)
Accumulated Amount
34,193
-
-
17,518
16,675(95.2%)
-
-
-
-
-
-
2. Details of Information Released
Information Providers
Management Support Division
Information Recipients
Institutional Investor, Analyst, etc.
Date&Time of Information Released
2022-02-25
Title and Place of Event held
-
3. Contact Points
Disclosure Officer (tel.)
CEO Kichul Cha (02-501-3939)
Disclosure Staff (tel.)
Vice President Woosung Bang (02-501-3939)
Dept. Name (tel.)
Management Support Division (02-501-3939)
4. Other references useful for making investment decisions
- The above results are consolidated financial statements based on K-IFRS.
- The 2021 data provided in this document is for investor convenience only and has not been approved by the external auditor. The results above are currently under audited by the external auditor and might be subject to change.
※ Relevant Disclosure
-
Attachments
Original Link
Original Document
Permalink
Disclaimer
InBody Co. Ltd. published this content on 25 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 February 2022 06:51:03 UTC.
InBody Co., Ltd., formerly Biospace Co., Ltd., is a Korea-based company engaged in the manufacture of electronic medical devices. The Company mainly produces body composition analyzers under the brand names of InBody and LookinâBody. The Company mainly produces body composition analyzers under the brand name InBody and LookinâBody. Its InBody series products include InBody720, InBody520, InBody230, InBody R20, InBody S20, InBody S10 and InBody J10. Its Lookin' series products include LookinâBody3.0 and LookinâBody Basic, which are used for measuring proteins, minerals, fats, moistures and others. It also provides body mass index (BMI) measuring devices under the brand name of BSM. The Company distributes its products within domestic market and to overseas markets.
INBODY CO.,LTD 
